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The overlap of symptoms between neurodegenerative and psychiatric diseases has
been reported. Neuropsychiatric alterations are commonly observed in dementia,
especially in the behavioral variant of frontotemporal dementia (bvFTD), which is the most
common clinical FTD subtype. At the same time, psychiatric disorders, like schizophrenia
(SCZ), can display symptoms of dementia, including features of frontal dysfunction
with relative sparing of memory. In the present review, we discuss common molecular
features in these pathologies with a special focus on FTD. Molecules like Brain Derived
Neurotrophic Factor (BDNF) and progranulin are linked to the pathophysiology of both
neurodegenerative and psychiatric diseases. In these brain-associated illnesses, the
presence of disease-associated variants in BDNF and progranulin (GRN) genes cause
a reduction of circulating proteins levels, through alterations in proteins expression or
secretion. For these reasons, we believe that prevention and therapy of psychiatric and
neurological disorders could be achieved enhancing both BDNF and progranulin levels
thanks to drug discovery efforts.
Keywords: BDNF, progranulin, biomarkers, frontotemporal dementia, psychiatric disorders, neurodegenerative
diseases
INTRODUCTION
Over the past 10 years frontotemporal lobar degeneration (FTLD) has emerged, along with
Alzheimer disease (AD), as a leading cause of dementia developing in midlife or earlier (Ratnavalli
et al., 2002; Onyike and Diehl-Schmid, 2013). Identification of FTLD-causing genetic alterations
has been complex due to the variety of genes involved and the different protein functions. While
the majority of FTLD cases are sporadic, approximately 40% of patients have a positive family
history (Gass et al., 2012) and about 10% show a clear autosomal-dominant inheritance, suggesting
the involvement of genetic components in the etiology of this disorder (Snowden et al., 2002;
Seelaar et al., 2008; Rohrer et al., 2009; Benussi et al., 2015). Genetic studies have identified several
genes linked to FTLD: microtubule-associated protein tau (MAPT), progranulin (GRN), TAR
DNA-binding protein 43 (TDP-43), valosin-containing protein (VCP), charged multivesicular
body protein 2B (CHMP2B), fused in sarcoma (FUS), and the hexanucleotide repeat expansion
in intron 1 of the chromosome 9 open reading frame 72 (C9ORF72; Hutton et al., 1998; Watts
et al., 2004; Skibinski et al., 2005; Baker et al., 2006; Cruts et al., 2006; Broustal et al., 2010;
DeJesus-Hernandez et al., 2011; Renton et al., 2011; Rohrer et al., 2015). The neuropathology of
FTLD is heterogeneous and subtypes can be distinguished depending on the protein deposited
in inclusion bodies in the central nervous system (CNS; Mackenzie et al., 2010). These protein
inclusions within neurons and glial cells together with degeneration of the brain’s frontal and
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temporal lobes are considered the primary neuropathological
hallmark of FTLD (Gass et al., 2012). The most common
clinical subtype of frontotemporal dementia is the behavioral
variant (bvFTD), which is characterized by progressive
behavioral changes, such as disinhibition, apathy/inertia,
loss of sympathy/empathy, perseverative, stereotyped and
compulsive/ritualistic behavior and hyperorality (Rascovsky
et al., 2011). These psychiatric symptoms in FTLD
mutation carriers can be very similar to those seen in non-
neurodegenerative psychiatric illness (Block et al., 2015). Thus,
bvFTD can mimic several psychiatric conditions, such as mood
disorders (MD), obsessive–compulsive disorder (OCD) and
schizophrenia (SCZ; Wylie et al., 2013). In parallel, some
psychiatric disorders, notably SCZ, can progress to a syndrome
of dementia that includes features of frontal dysfunction with
relative sparing of memory (Friedman et al., 2001; Harvey, 2012).
Moreover, bvFTD behavioral symptoms are often controlled by
therapies that are available for psychiatric disorders, while no
medication has been found to stabilize or improve their cognitive
dysfunction (Vossel and Miller, 2008). A similar overlap of
symptoms with psychiatric disorders has been observed not only
in bvFTD, but also in other forms of dementia such as AD and
Lewy Bodies Dementia (LBD). Neuropsychiatric symptoms,
such as apathy, depression, delusion, aggression, physical and
verbal agitation, are frequent in LBD and AD, even in the early
stages of the disease, and are very distressing to patient caregivers
(Nagahama et al., 2010; Lyketsos et al., 2011).
There is a pressing need to identify molecular pathways
underlying neuropsychiatric symptoms in psychiatric disorders
and dementias. Molecular links between neurodegeneration and
psychiatric phenotype have been reported: (i) a recent study
shows a decrease of progranulin plasma levels in subjects with
bipolar disorder (BD; Kittel-Schneider et al., 2014); (ii) new data
have suggested a role of amyloid-beta (Aβ) oligomers in memory
impairment, depressive and anhedonic behavior in mice (Ledo
et al., 2013); and (iii) transgenic mice overexpressing alpha-
synuclein—involved in Parkinson’s disease and LBD—show late-
onset anxiety behavior (Campos et al., 2013) and extracellular
alpha-synuclein oligomers modulate synaptic transmission and
impair Long Term Potentiation (LTP) via NMDA-receptor
activation (Diógenes et al., 2012). The serotonergic system,
classically involved in the depression/anxiety mechanisms, is
now proposed to regulate Aβ precursor protein (APP) activity
and metabolism (Shen et al., 2011), while Brain Derived
Neurotrophic Factor (BDNF) has a relevance not only in MD,
but also in depression-associated cognitive decline (Diniz et al.,
2014). In vivo evidence suggests that Aβ aggregation dramatically
influence BDNF cerebrospinal fluid (CSF) level in transgenic AD
mouse models (Peng et al., 2009), underlining the importance of
this neurotrophic factor in AD pathogenesis, as already suggested
by genetic studies (Ventriglia et al., 2002; Chen et al., 2014).
Moreover, a peculiar CSF Aβ peptide signature was associated
to cognitive decline in SCZ, suggesting a dysmetabolism of APP
also in this psychiatric disorder (Frisoni et al., 2011; Albertini
et al., 2012). In addition, experimental studies showed that the
levels of progranulin were significantly correlated with amyloid
amount in mouse models of AD, detecting an increase of its
levels in mice with extensive dense-core plaques (Minami et al.,
2014).
Thus, mechanisms underlying neurodegenerative diseases
and psychiatric disorders converge on the same proteins within
different pathways. In this review, we will focus on the role of
BDNF and progranulin in these pathologies.
OUR PROTAGONISTS
BDNF is the most studied and characterized neurotrophin in the
CNS and it has received remarkable attention from clinicians
because of its importance in the development and maintenance
of normal brain functions. In humans, the BDNF gene is located
on the short arm of chromosome 11p13 (Pruunsild et al.,
2007). The gene comprises 11 exons, each coding for the 5′
untranslated region, spliced to a common downstream 3′ exon
IX. BDNF is the result of translation of at least 34 mRNA
transcripts and its expression is under the control of nine
alternative tissue-specific promoters (Pruunsild et al., 2007).
BDNF peptide is synthesized as its pro-isoform (pro-BDNF);
proteolytical cleavage into its mature form occurs within the
neuron or extracellularly, after secretion (Barker, 2009). Whereas
pro-isoforms such as pro-BDNF bind to p75 neurotrophin
receptor (p75NTR), the mature neurotrophins bind to protein-
kinase neurotrophin receptors—namely tropomyosine-related
kinase (Trk) receptors (Huang and Reichardt, 2003). BDNF
binds to Trk B of the family of Trk receptors, a process that
activates survival mechanisms in the CNS such as proliferation,
growth, and neuroplasticity (Islam et al., 2009; Nguyen et al.,
2009). In contrast, pro-BDNF activates apoptotic pathways
after binding to p75NTR (Teng et al., 2005) and induce
neuronal remodeling including axonal and dendritic pruning
(Barker, 2009; Koshimizu et al., 2009). BDNF, also thanks
to its notable activity-dependent regulation of expression and
secretion, seems to play an important role in neuronal plasticity,
defined as a set of mechanisms that may conduct to neuronal
reshaping, birth of new neurons and formation of novel
synapses (Bramham and Messaoudi, 2005). This is especially
important since growing evidence suggests a role for BDNF
in the pathophysiology of brain-associated illnesses including
both neurodegenerative and psychiatric diseases (Nagahara and
Tuszynski, 2011).
Progranulin is a multi-functional secreted adipokine of
593 amino acids with trophic, anti-inflammatory and growth
factor-like properties, characterized by dynamic changes in the
expression level, glycosylation status and cellular localization
during development and in the adult organism (Daniel et al.,
2000, 2003; Petkau et al., 2010). The human progranulin gene
(GRN) is located on chromosome 17q21.32 and it is composed
of 12 protein-coding exons. Alternative splicing and exon
skipping define three different progranulin isoforms (Bhandari
and Bateman, 1992; Bhandari et al., 1992). The protein is
characterized by a signal sequence and a series of seven and
a half granulin repeats (De Muynck and Van Damme, 2011)
separated by interlinked spacer regions, which are composed
of highly conserved tandem repeats of a unique 12-cysteine
motif (Shoyab et al., 1990; Bhandari and Bateman, 1992;
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Bhandari et al., 1992). After secretion, in peripheral tissues the
proteolytic cleavage of progranulin at the intra-linker spacer
regions give rise to several ∼6 kDa peptides called granulins
(Butler et al., 2008; Kessenbrock et al., 2008; Bai et al., 2009).
However, the full length progranulin can be preserved from
cleavage by secretory leukocyte protease inhibitor (SLPI; Zhu
et al., 2002) and high-density lipoprotein (HDL)/Apolipoprotein
A-I complex (Okura et al., 2010). Both progranulin precursor
and its cleavage fragments are biologically active in a series
of physiologic and pathological processes, showing opposing
roles in different biological functions (De Muynck and Van
Damme, 2011). Progranulin protein has many roles inside
and outside the brain, acting through the extracellular signal-
regulated kinase and phosphatidylinositol-3-kinases pathways
(Toh et al., 2011). Progranulin is involved in multiple biological
functions, such as in survival, migration and regulation of cellular
proliferation, wound repair and inflammation, and it has also
been speculated to play a role in excitotoxicity and synaptic
transmission (Guo et al., 2010; Tapia et al., 2011). Specifically,
in the CNS, progranulin seems to play a significant role in
maintaining physiological functions because it has been observed
that it has neuroprotective effects (Van Kampen et al., 2014) and
neurotrophic activity in vitro and in vivo model systems (Van
Damme et al., 2008; Gao et al., 2010; Laird et al., 2010). Multiple
evidence supports that progranulin is involved in different
pathological conditions, such as neurodegenerative, psychiatric
and metabolic disorders, thus becoming a fascinating target for
therapy (Philips et al., 2010; Petkau and Leavitt, 2014; Kanazawa
et al., 2015).
Taken together these data highlight neurotrophic properties
for both BDNF and progranulin with a significant role in
synaptic density andmorphology. Further cellular andmolecular
studies indicate similar functions and participation in common
pathways for our protagonists. The identification of sortilin 1
(SORT1) as the principal neuronal receptor for progranulin
was important for our understanding of progranulin biology.
SORT1 is a sorting protein involved in endocytosis and transport
to trans-golgi network and endosomes: when progranulin is
bound to SORT1 it is immediately endocytosed and delivered
to the lysosome. Indeed, the uptake of progranulin via SORT1
defines a substantial reduction of extracellular progranulin levels
(Petersen et al., 1997). Recently, a determinant role for SORT1
has been described in the pathogenesis of FTLD: deletion of
this receptor results in a 2.5 to 5-fold increase in progranulin
levels and reversal of progranulin deficiency in theGRN ± FTLD
model (Hu et al., 2010). Thus, SORT1 is an important regulator
of progranulin extracellular levels, while the neurotrophic and
neuroprotective effects of progranulin are independent from
its uptake mediated by SORT1 receptor (De Muynck et al.,
2013). Of note, SORT1 also plays an important role in the
biological function of BDNF. It plays an essential role in
the regulation of BDNF levels through modulation of both
anterograde and lysosomal trafficking (Chen et al., 2005; Evans
et al., 2011). Moreover, SORT1 can form a complex with p75NTR
and ProBDNF to induce cell death; on the other hand, SORT1
has also been implicated in anterograde trafficking of the Trk
receptors from the soma to the nerve terminal, thereby positively
regulating BDNF signaling and cell survival (Vaegter et al.,
2011).
The presence of common function of the two proteins is
further supported by a recent study reporting that progranulin
is co-localized with dense-core vesicle markers and is further
recruited to synapses following neuronal activity. Furthermore,
the authors observed that, similarly to what is described for
BDNF, progranulin is secreted from axons and dendrites in an
activity-dependent manner with different temporal profiles of
secretion. Treatment of neurons with recombinant progranulin
was shown to increase synapse density, while decreasing the size
of the presynaptic compartment and specifically the number of
synaptic vesicles per synapse (Petoukhov et al., 2013). In parallel,
a study has demonstrated that acute and gradual increases in
BDNF concentration activate different intracellular cascades,
leading to differences in spine morphology (Ji et al., 2010). These
results suggest that it is not only the concentration of secreted
BDNF that it is important for the regulation of neuronal function
and morphology, but also the manner in which it is secreted:
constitutively or in response to neuronal activity. It is possible
that constitutive and regulated secretion of progranulin also
differentially regulates synapse structure and function.
BDNF AND PROGRANULIN IN FTLD AND
RELATED NEURODEGENERATIVE
DISEASES
Current hypotheses state that the crucial point in the progression
of neurodegenerative diseases is driven by deterioration of
synapses. This is supported by synapse loss being observed as
a major pathophysiological hallmark in all neurodegenerative
diseases. BDNF, thanks to its role in synaptogenesis, becomes
the best pawn on the chessboard with respect to counteracting
synaptic function loss. A reduction of hippocampal BDNF levels
not only reduced the number of synapses, but also impaired
LTP and caused deficits in the formation and consolidation of
hippocampus-dependent memory (Linnarsson et al., 1997; Ma
et al., 1998; Mu et al., 1999).
Neurotrophins can protect synapses against various toxic
insults in animal models of neurodegenerative diseases, such
as AD, Huntington’s disease, Amyotrophic Lateral Sclerosis
and Parkinson’s disease (PD; Nagahara and Tuszynski, 2011).
Remarkably, BDNF has been shown to protect and/or repair
hippocampal neurons and synapses despite Aβ accumulation and
neuronal toxicity in a mouse model of AD (Nagahara et al.,
2009) and to rescue plasticity deficits induced by synthetic Aβ
oligomers in rat hippocampal slices ex vivo (Zeng et al., 2010).
This suggests a therapeutic potential in presence of pathogenic
factors (Lu et al., 2013). Furthermore, transplantation of neural
stem cells (NSC) secreting BDNF in AD model mice also
improved cognitive function (Blurton-Jones et al., 2009). BDNF-
based therapy is therefore increasingly expected to ameliorate
the symptoms of AD (Nagahara et al., 2009; Peng et al., 2009;
Devi and Ohno, 2012; Adachi et al., 2014). Decreased expression
levels of BDNF protein and mRNA have been consistently
reported in the hippocampus and cortex of individuals with
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AD (Phillips et al., 1991; Connor et al., 1997; Hock et al.,
2000; Holsinger et al., 2000) as well as in serum (Laske et al.,
2007). Belrose et al. (2014) analyzed neurotrophins alterations
in patients with different tauopathies, observing a significant
decrease in BDNF mRNA and protein levels in Pick’s disease
and corticobasal degeneration. A further study on the role of
this neurotrophin in different neurological diseases observed
lower levels of BDNF protein in serum of FTLD AD, LBD and
vascular dementia patients, whereas the protein was increased
in PD patients (Ventriglia et al., 2013). In the BDNF gene, a
functional polymorphism (SNP, rs6265) has been characterized,
producing a valine (Val) to methionine (Met) substitution at the
codon 66 (Val66Met) in the proBDNF region. The valine-for-
methionine substitution is associated with inefficiency inactivity-
dependent transportation of BDNF mRNA (Chiaruttini et al.,
2009) and protein to dendrites (Egan et al., 2003; Chen et al.,
2004), thus contributing to reductions in dendritic density,
deficits in synaptic connectivity, and neurocognitive deficits
(Egan et al., 2003; Chen et al., 2004). Indeed, inheritance of the
BDNF Met allele might be expected to confer susceptibility to or
modifying the expression of conditions that impact adversely on
hippocampal function, as measured also by functional magnetic
resonance imaging (Egan et al., 2003; Hariri et al., 2003;
Dempster et al., 2005; Nagahara and Tuszynski, 2011).
It has been reported that BDNF Val66Met polymorphism
may play a role as a genetic risk factor and diseases modulator
for FTLD and may drive a selective damage in specific brain
region affected by the disease (Borroni et al., 2012). Due to its
role on neuronal function and survival in different systems in
the CNS, BDNF is an interesting candidate for drug discovery.
Strategies that aim to achieve safe and effective, dose-continuous
delivery of BDNF in the brain, as drug-induced increasing BDNF,
exercise and diet, epigenetic or peptide mimetic of BDNF, seem
promising (Nagahara and Tuszynski, 2011).
Loss-of-function mutations in GRN are a common cause of
FTLD. Since 2006, more than 70 distinct pathogenic mutations
have been identified in the GRN gene, accounting for up to
20% of familial and 5% of sporadic FTLD cases (Cruts et al.,
2012). Most of these pathogenic alterations are characterized
as nonsense, frameshift and splice site mutations causing a
premature stop codon, even if other mechanisms have also been
observed (Ghidoni et al., 2008; Gass et al., 2012). All pathogenic
mutations identified cause disease by protein haploinsufficiency
(Baker et al., 2006; Ghidoni et al., 2008; Finch et al., 2009; Sleegers
et al., 2009; Cruts et al., 2012) leading to a ∼50% or greater
decrease in progranulin levels in the blood, unaffected brain
regions and CSF of GRN mutated subjects (Coppola et al., 2008;
Ghidoni et al., 2008, 2012; Finch et al., 2009; Sleegers et al.,
2009). Furthermore, circulating progranulin levels have been
proposed as a useful biomarker for a quick and inexpensive large-
scale screening of GRN mutation carriers (Ghidoni et al., 2012).
Though all GRN null mutations cause the disease through this
common mechanism, linked to the degradation of RNA through
non-sense mediated decay (Baker et al., 2006; Cruts et al.,
2006), the spectrum of clinical presentations associated with
mutations in GRN is heterogeneous: however, the bvFTD is the
most common clinical presentation, characterized by progressive
behavioral changes (Gass et al., 2006; Rademakers et al., 2007;
Beck et al., 2008; Le Ber et al., 2008; Benussi et al., 2009).
In addition to null mutations, GRN polymorphic variants,
located in the promoter and in the 3′ untranslated region, have
been described to increase the risk to develop FTLD, possibly
by influencing the transcription of the gene (Rademakers et al.,
2008; Galimberti et al., 2010). The GRN gene expression is
also regulated by DNA methylation in its core promoter region
(Banzhaf-Strathmann et al., 2013). Interestingly, an increased
methylation of GRN promoter region was described in cells and
brains from FTLD, specifically in patients with bvFTD clinical
variant (Banzhaf-Strathmann et al., 2013; Galimberti et al., 2013).
Different lines of GRN-knockout mice have been produced
showing phenotypes that qualifiy them as useful models of FTD
(Kayasuga et al., 2007; Yin et al., 2010; Ghoshal et al., 2012).
Specifically, Yin et al. (2010) obtained progranulin-deficient
mice characterized by phenotypic alterations that resembles
what is typically observed in patients with bvFTD. All these
considerations suggest that progranulin represents a promising
target for treatment of different neurodegenerative diseases
(Boxer et al., 2013; Van Kampen et al., 2014).
Potential treatments to counteract progranulin loss in
neurodegeneration are in development because they could
represent a promising therapeutic strategy to decelerate
neurodegenerative progression or at least to alleviate the
symptoms associated with disease (Gass et al., 2012; Jing et al.,
2015). It has been observed that increasing progranulin levels
might reduce neuronal vulnerability to injury, inflammation and
other insults associated to increased risk of cell death and diseases
such as FTLD (Gass et al., 2012). Several chemical compounds,
such as Bafilomycin A1 (BafA1), alkalizing compounds and
suberoylanilide hydroxamic acid (Capell et al., 2011; Cenik et al.,
2011), and genetic factors, including different microRNAs and
also different genetic variants (Cruchaga et al., 2011; Finch et al.,
2011; van der Zee and Van Broeckhoven, 2011), have recently
been identified as enhancer of GRN expression, demonstrating
therapeutic potential in progranulin associated- FTLD. Maybe
the way to develop an efficacious therapy is still far away, but
these first results are encouraging.
BDNF AND PROGRANULIN IN
PSYCHIATRIC DISORDERS
Growing evidences suggest a role for BDNF in the
pathophysiology of brain-associated illnesses such as OCD
(Maina et al., 2010), attention deficit-hyperactivity disorder
(Scassellati et al., 2014), eating disorders (Monteleone et al.,
2006) substance abuse (Zanardini et al., 2011) as well as MD,
BD and SCZ (Sen et al., 2008; Adachi et al., 2014; Polyakova
et al., 2015). Rodent models of depression show reduced
expression levels of BDNF and its receptor Tropomyosin
receptor kinase B (TrkB). Different types of stressors on rodents
can reduce expression levels of BDNF in amygdala, cortex and
hippocampus (Stepanichev et al., 2014). Of note, direct BDNF
infusion into the rat midbrain induced antidepressant-like effects
(Siuciak et al., 1997). Patients suffering from depression exhibit
specific BDNF levels reduction in hippocampus and serum
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(Dwivedi et al., 2003; Bocchio-Chiavetto et al., 2010). Treatments
with antidepressant drugs reversed this condition (Sen et al.,
2008); this effect was also observed after repetitive transcranial
magnetic stimulation, a non-pharmacological intervention
(Zanardini et al., 2006). The role of BDNF in BD is unclear,
probably because the disease is characterized by different mood
states in which the expressiuon of neurotrophin is modulated
(Cunha et al., 2006; Yoshimura et al., 2006; de Oliveira et al.,
2009; Tramontina et al., 2009). In fact, a recent systematic
review and meta-regression analysis reported that peripheral
BDNF could be used as a biomarker for mood states and disease
progression in BD (Fernandes et al., 2011). Mood stabilizers
such as lithium or valproic acid are utilized to treat BD patients
and as happens also for antidepressant, increase the BDNF
expression (Hashimoto et al., 2002; Chen and Manji, 2006;
Sanacora, 2008). Furthermore, BDNF is also decreased in the
prefrontal cortex and hippocampus in an animal model of
mania (Frey et al., 2006). In addition, The V66M BDNF allele
is strongly associated with BD (Neves-Pereira et al., 2002;
Sklar et al., 2002; Lohoff et al., 2005). Moreover, Cattaneo
et al. (2010) describe an interesting reduction of BDNF in
amniotic fluid of Met carriers (Val/Met and Met/Met) as
compared to non carriers (Val/Val), supporting the involvement
of this polymorphism in behavioral and functional brain
individual differences. Animal studies show that BDNF controls
the development and activity of neurotransmitter systems
implicated in psychotic disorders (Tanaka et al., 1997; Mattson,
2008). Indeed, neurodevelopmental models of SCZ suggest that
reduced BDNF may affect synaptic efficiency and connectivity
in SCZ that is believed to underlie core behavioral signs and
symptoms of the disease (Lipska et al., 2003; Toro et al., 2007;
van Haren et al., 2008). There is no widespread agreement on
the degree of peripheral BDNF reduction in SCZ, as measured
in blood serum or plasma. Most studies report reduced BDNF
levels measured in blood from SCZ patients (Toyooka et al.,
2002; Pirildar et al., 2004; Grillo et al., 2007; Mackin et al., 2007;
Ikeda et al., 2008; Lee and Kim, 2009; Xiu et al., 2009; Jindal
et al., 2010), whereas two studies describe higher levels of BDNF
concentration in serum of schizophrenic patients compared
with healthy controls (Gama et al., 2007; Reis et al., 2008).
There are also studies that report no significant difference in
BDNF plasma levels in non-medicated SCZ patients compared
with controls, while increased BDNF levels observed in these
same subjects following antipsychotic treatment (Lee and
Kim, 2009). Some studies evidence altered BDNF mRNA and
protein levels in prefrontal cortical regions of post-mortem
brain tissue of schizophrenic subjects (Durany et al., 2001;
Mellios et al., 2009; Wong et al., 2010), with variation reported
across different brain regions (Durany et al., 2001; Hashimoto
et al., 2005). Several researchers have focused their attention
on DNA methylation as a repressive mechanism for BDNF
gene expression, potentially linked to pathogenesis of mental
diseases (Tsankova et al., 2007; Mill et al., 2008; Fuchikami
et al., 2011). Reduced BDNF gene expression in combination
with a considerable increase of promoter methylation levels,
was selectively detected in BD type II subjects (BD-II), but
not in BD I group (BD-I) with respect to controls. This result
confirms a prior study demonstrating that BDNF expression
is decreased in chronic or later stages of BD compared with
early stages of disease (Kauer-Sant’Anna et al., 2009). This
suggests that attempting to therapies that may be useful to
restore a correct degree of methylation could be beneficial
(Nan et al., 1998; Fuks et al., 2000; Garcia-Manero et al., 2006;
Candelaria et al., 2007). It has been largely demonstrated
that mutations in GRN cause FTLD. It is less known that
common genetic polymorphisms in this gene are associated
with SCZ and bipolar affective disorder (Rademakers et al.,
2008; Momeni et al., 2010; Schoder et al., 2010; Galimberti
et al., 2012, 2014). A systematic literature analysis reveals that
psychosis is a frequent symptom in FTD in the presence of
genetic mutations in GRN and C9ORF72 genes (Shinagawa
et al., 2014); in C9ORF72 carriers, psychotic symptoms can even
predominate at onset and lead to a diagnosis of OBC, SCZ or
BD (Rohrer et al., 2015). At present, the effects of progranulin
impairment in psychiatric diseases have not yet been studied in
specific animal models. However, since (i) mutations in GRN
cause bvFTD and (ii) GRN knock-out models are characterized
by prominent behavioral disturbances, the study of such
animal models could be useful to understand the molecular
mechanisms underlying psychiatric disorders (Roberson, 2012).
Galimberti et al. performed an association study in which they
analyzed the correlation between progranulin gene variations
and the risk for developing BD in patients with BD-I and
BD-II (Galimberti et al., 2012, 2014): the specific GRN SNP
rs5848, which is associated with variation in progranulin levels
(Galimberti et al., 2014), resulted to be a protective factor
associated with BD-I, but not with BD-II, probably due to
different pathogenic mechanisms among the two subtypes of
diseases. In addition, they observed progranulin plasma levels
significantly lower in the whole BD population compared with
controls, even if they did not exclude the effect of the therapy
on progranulin levels. This previous finding was confirmed
by a larger replication analysis (Kittel-Schneider et al., 2014).
Moreover, also in this BD cohort it has been observed that age
has a significant effect on progranulin levels, with increasing
levels in higher age, data which is coherent with what previously
reported in FTLD patients (Ghidoni et al., 2008). From a
clinical point of view, a high phenotypic variability is associated
with GRN mutations, even in the same family (Benussi et al.,
2009; Momeni et al., 2010; Pietroboni et al., 2011): specifically,
Momeni et al. (2010) studied a Latino family in which SCZ
and FTD coexisted, suggesting a molecular link between FTD,
SCZ and GRN mutations. Another study reported that the
morbid risk for SCZ is significantly increased in first-degree
relatives of subjects with FTD with respect to first-degree
relatives of people with AD; in addition, in three families with a
known GRN mutation, there was a co-segregation of mutation
and SCZ (Schoder et al., 2010). Though the concomitance of
FTD and SCZ has been reported in few family pedigrees, the
pathogenic mechanism of loss of function GRN mutations is
consistent with the neurodevelopmental hypothesis of SCZ,
as the haploinsufficiency exist throughout development and
childhood (Rapoport et al., 2005; Fatemi, 2009). Accordingly,
progranulin concentrations were significantly higher in pregnant
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women compared to post-partum levels (Todoric et al., 2012),
confirming its role during embryonic development (Daniel
et al., 2003). In this view, psychiatric disorders might represent
a long lasting preclinical phase preceding FTD in some GRN
mutation carriers (Momeni et al., 2010). In line with these data,
it’s important to note that two clinically different GRN mutated
FTLD cases (one with bvFTD and one with progressive non
fluent aphasia) showed a premorbid BD status (Cerami et al.,
2011).
CONCLUDING REMARKS
In this review, we described how BDNF and progranulin proteins
are involved in psychiatric and neurodegenerative diseases.
We found that our protagonists share common molecular
features in these pathologies. Specifically we noticed that: (i)
Circulating BDNF and progranulin protein levels are reduced in
pathological conditions: a decrease of BDNF levels was observed
in MD and BD as well as in FTLD and related disorders;
in parallel, a reduction of progranulin was detected not only
in GRN-associated FTLD, but also in BD; (ii) for BDNF and
GRN genes, the disease-associated variants cause a reduction
in protein levels: the BDNF Val66Met polymorphism, a risk
factor for BD and FTLD, results in a impaired secretion of
the protein; (iii) in parallel, the whole panel of pathogenic
GRN mutations as well as polymorphisms cause reduced
protein expression or secretion, although by different cellular
mechanisms; (iv) both BDNF and GRN promoters are highly
methylated in pathological conditions: a different degree of
methylation, and consequently a reduction of gene expression,
was observed in BDNF and GRN promoter regions in BD and
FTLD, respectively; and (v) equally BDNF and progranulin are
involved in neurodevelopment and neuroplasticity: an insult
or a genetic defect might unbalance the expression of these
neurotrophins in specific brain regions and in different period
of life and thus results in either neurodegenerative or psychiatric
diseases.
In this view, we may speculate that, as suggested by Momeni
et al. (2010) for subjects with progranulin deficit, psychiatric
disorders might represent a preclinical phase preceding FTD.
Given all these similarities, we believe that drug discovery
effort aimed at enhancing both BDNF and progranulin levels is
of great interest for the prevention and cure of psychiatric and
neurological disorders.
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